ResMed Inc.
Financials
Valuation Metrics
ResMed Inc.'s Market Cap is $33.79B. At end of 2025 it was $35.20B. Ranked #399 of 3,114 in US market (top 13%), #284 of 1,642 on NYSE (top 17%), #26 of 203 in Health Care Equipment & Services (top 13%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $33.79B | US#399/3,114 Sec#26/203 |
| Revenue | $5.65B | US#818/3,114 Sec#48/203 |
| Net Income | $1.52B | US#405/3,114 Sec#19/203 |
| Total Assets | $8.97B | US#1,048/3,114 Sec#50/203 |
| Net Assets | $6.59B | US#571/3,114 Sec#34/203 |
| Employees | 11,370 | US#801/3,114 Sec#60/203 |
| Value | ||
| P/E | 22.18x | US#1,350/3,114 Sec#40/203 |
| P/B | 5.13x | US#2,296/3,114 Sec#138/203 |
| PEG | 2.54x | US#1,092/3,114 Sec#55/203 |
| P/S | 5.98x | US#2,472/3,114 Sec#159/203 |
| EV/EBITDA | 15.44x | US#1,679/3,114 Sec#69/203 |
| FCF Yield | 8.55% | US#847/3,114 Sec#29/203 |
| Profitability | ||
| ROE | 23.13% | US#465/3,114 Sec#23/203 |
| ROA | 16.99% | US#175/3,114 Sec#8/203 |
| Op. Margin | 33.48% | US#429/3,114 Sec#5/203 |
| Revenue Growth | 9.85% | US#1,260/3,114 Sec#86/203 |
| Earnings Growth | 8.75% | US#1,096/3,114 Sec#60/203 |
| Financial Health | ||
| Debt Ratio | 36.15% | US#410/3,114 Sec#43/203 |
| Total Debt | $826M | US#1,623/3,114 Sec#88/203 |
| FCF | $2.89B | US#275/3,114 Sec#19/203 |
| Cash | $1.47B | US#536/3,114 Sec#29/203 |
| Current Ratio | 3.10x | US#751/3,114 Sec#74/203 |
| Net Debt/EBITDA | -0.30x | US#465/3,114 Sec#36/203 |
| Dividend | ||
| Div. Yield | 1.03% | US#1,327/3,114 Sec#28/203 |
| Div. Growth | 10.34% | US#489/3,114 Sec#15/203 |
| Performance | ||
| 1Y Return | -5.20% | US#1,816/3,114 Sec#129/203 |
| 1M Return | 6.42% | US#354/3,114 Sec#36/203 |
| From 52W High | -15.91% | US#744/3,114 Sec#71/203 |
| 1Y MDD | -33.60% | US#1,554/3,114 Sec#90/203 |
| Trading | ||
| Volume | 1,262,333 shares | US#1,634/3,114 Sec#107/203 |
| Trading Value | $292M | US#493/3,114 Sec#41/203 |
| Per Share | ||
| EPS | $10.50 | US#278/3,114 Sec#18/203 |
| BPS | $45.40 | US#508/3,114 Sec#35/203 |
Company Info
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.